Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth

Fineline Cube Apr 16, 2026
Company Deals

Ty Biotech and Shenzhen University Launch Joint Institute for Chlamydomonas-Based Biopharmaceutical Development with $73 Million Investment

Fineline Cube Apr 16, 2026
Company Deals

Insilico Medicine and Ancestor Cell Forge AI-Stem Cell Alliance to Accelerate Exosome Therapeutics Development

Fineline Cube Apr 16, 2026
Company Deals

GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235

Fineline Cube Apr 16, 2026
Company Deals

Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision

Fineline Cube Apr 16, 2026
Policy / Regulatory

China’s State Council Unveils Comprehensive Drug Pricing Reforms to Strengthen Market-Oriented Mechanisms and Innovation Incentives

Fineline Cube Apr 15, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty

Fineline Cube Apr 16, 2026
Company Drug

Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration

Fineline Cube Apr 16, 2026
Company Drug

Akeso Biopharma Initiates Phase II Global Study for Ligafulimab in High-Risk MDS

Fineline Cube Aug 5, 2024

China-based Akeso Biopharma (HKG: 9926) has reached a clinical milestone with the dosing of the...

Company

Astellas Pharma Reports Robust Q1 FY2024 Results, Highlighting Growth in Core Therapies

Fineline Cube Aug 5, 2024

Japan-based Astellas Pharma Inc. (TYO: 4503) has announced its financial results for the first quarter...

Policy / Regulatory

China’s NMPA Launches Pilot Programs in Beijing and Shanghai for Innovative Drug Approvals

Fineline Cube Aug 2, 2024

The National Medical Products Administration (NMPA) of China has given the green light to Beijing...

Policy / Regulatory

China’s State Council Unveils Guidelines to Enhance Basic Medical Insurance System

Fineline Cube Aug 2, 2024

In a bid to address the evolving healthcare needs of an aging population and a...

Company Drug

AbbVie Completes Acquisition of Cerevel Therapeutics in $8.7 Billion Deal

Fineline Cube Aug 2, 2024

US pharmaceutical giant AbbVie Inc. (NYSE: ABBV) has announced the successful completion of its acquisition...

Company Medical Device

Sino Medical Sciences’ HT Supreme Drug-Eluting Stent System Gains Market Approval in Mexico

Fineline Cube Aug 2, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), a prominent player in the medical device industry...

Company Drug

Lee’s Pharmaceutical Commences Phase I Clinical Trial for AI-Discovered HCC Drug AU409

Fineline Cube Aug 2, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading biopharmaceutical company based in China, has announced...

Company Medical Device

Roche’s Alzheimer’s Disease Diagnostic Kits Gain Approval in Hainan, Set for Use in Shanghai Ruijin Hospital

Fineline Cube Aug 2, 2024

Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has received approval from the Hainan Medical...

Company Deals

Mabwell Bioscience Secures Rights to Risen Pharmaceutical’s OA Treatment in Greater China

Fineline Cube Aug 2, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a leading biopharmaceutical company in China, has entered...

Company Drug

Suzhou Zelgen’s Jacktinib Tablets Achieve Positive Results in Phase II IPF Clinical Trial

Fineline Cube Aug 2, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company Deals

ImmuneOnco Biopharmaceuticals Strikes Licensing Deal with Instil Bio for Global Rights to Dual-Targeted Antibodies

Fineline Cube Aug 2, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has entered into a definitive licensing agreement with...

Company Drug

Sino Biopharmaceutical’s Benmelstobart Files for New Indication in China for Advanced RCC Treatment

Fineline Cube Aug 2, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced that...

Company Medical Device

AbbVie’s Allergan Aesthetics Wins NMPA Approval for Juvéderm Dermal Filler in China

Fineline Cube Aug 2, 2024

Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has secured marketing approval from China’s National...

Company Drug

Innovent Biologics’ Mazdutide NDA for Type 2 Diabetes Accepted for Review in China

Fineline Cube Aug 2, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company in China, has announced that the...

Company Drug

GSK’s Jemperli Receives EC Approval for Endometrial Cancer Treatment in Combination Therapy

Fineline Cube Aug 2, 2024

GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced that the European Commission...

Company Deals

Fapon Biotech Expands Global Footprint with New IVD Manufacturing Facility in Indonesia

Fineline Cube Aug 2, 2024

China-based in vitro diagnostic (IVD) company Fapon Biotech has announced a strategic investment with the...

Company Deals

Kyowa Kirin Revamps APAC Strategy, Exits China and Shifts R&D Focus

Fineline Cube Aug 2, 2024

Japan’s pharmaceutical group Kyowa Kirin Co., Ltd (TYO: 4151) has announced a significant restructuring of...

Company Deals

Otsuka Pharmaceutical to Acquire US Biotech Jnana Therapeutics in $1.1 Billion Deal

Fineline Cube Aug 2, 2024

Otsuka Pharmaceutical Co., Ltd, a leading Japanese pharmaceutical company, has announced the signing of a...

Policy / Regulatory

US Lawmakers Probe Clinical Trials at Hospitals Linked to Chinese Military, Potential Impact on Pharma Industry

Fineline Cube Aug 1, 2024

Reports from BioCentury and Endpoints News, based on anonymous insider sources, suggest that US lawmakers...

Policy / Regulatory

China’s Health Authorities Set Standards for Key Central Township Health Centers

Fineline Cube Aug 1, 2024

The National Health Commission (NHC), National Disease Control and Prevention Administration, and National Administration of...

Posts pagination

1 … 306 307 308 … 652

Recent updates

  • RemeGen Receives $650 Million Upfront from AbbVie in Landmark $5.6 Billion Bispecific Antibody Licensing Deal
  • Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty
  • Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration
  • Sino Biopharmaceutical Initiates Phase III Trial of LM-302 ADC Combined with Anti-PD-1 for CLDN18.2-Positive Gastric Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

RemeGen Receives $650 Million Upfront from AbbVie in Landmark $5.6 Billion Bispecific Antibody Licensing Deal

Company Deals

Annoroad Gene Technology Files Hong Kong IPO Prospectus to Capitalize on China’s Molecular Diagnostics Growth

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for HRS-7156, a First-in-Class Heart Failure Therapy with Global Novelty

Company Drug

Gan & Lee Pharmaceuticals Secures NMPA Clinical Approval for GLR1062, China’s First-in-Class Gene Therapy for Wet Age-Related Macular Degeneration

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.